x
|
Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934 for the Quarter Ended March 31,
2007
|
o
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934
|
Delaware
|
04-2209186
|
(State
of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
|
|
81
Wyman Street, P.O. Box 9046
|
|
Waltham,
Massachusetts
|
02454-9046
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Class
|
|
Outstanding
at March 31, 2007
|
||
Common
Stock, $1.00 par value
|
|
421,930,107
|
March
31,
|
December
31,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
(Unaudited)
|
|||||||
Current
Assets:
|
|||||||
Cash
and cash equivalents
|
$
|
670.9
|
$
|
667.4
|
|||
Short-term investments, at quoted market value (amortized cost of
$23.9
and $23.8)
|
20.5
|
23.8
|
|||||
Accounts
receivable, less allowances of $50.9 and $45.0
|
1,419.0
|
1,392.7
|
|||||
Inventories:
|
|||||||
Raw
materials
|
322.4
|
307.7
|
|||||
Work
in process
|
134.1
|
121.7
|
|||||
Finished
goods
|
724.0
|
735.1
|
|||||
Deferred
tax assets
|
225.3
|
209.2
|
|||||
Other
current assets
|
230.0
|
201.9
|
|||||
3,746.2
|
3,659.5
|
||||||
Property,
Plant and Equipment, at Cost
|
1,578.5
|
1,533.0
|
|||||
Less:
Accumulated depreciation and amortization
|
322.3
|
276.3
|
|||||
1,256.2
|
1,256.7
|
||||||
Acquisition-related Intangible Assets, net of Accumulated Amortization
of
$445.2 and $276.4
|
7,333.2
|
7,511.6
|
|||||
Other
Assets
|
258.3
|
309.4
|
|||||
Goodwill
|
8,578.0
|
8,525.0
|
|||||
$
|
21,171.9
|
$
|
21,262.2
|
March
31,
|
December
31,
|
||||||
(In
millions except share amounts)
|
2007
|
2006
|
|||||
(Unaudited)
|
|||||||
Current
Liabilities:
|
|||||||
Short-term obligations and current maturities of long-term
obligations
|
$
|
167.4
|
$
|
483.3
|
|||
Accounts
payable
|
679.6
|
630.8
|
|||||
Accrued
payroll and employee benefits
|
196.2
|
253.3
|
|||||
Accrued
income taxes
|
38.4
|
60.3
|
|||||
Deferred
revenue
|
138.4
|
121.3
|
|||||
Other
accrued expenses (Notes 2, 10 and 11)
|
576.5
|
603.3
|
|||||
1,796.5
|
2,152.3
|
||||||
Deferred
Income Taxes
|
2,483.8
|
2,557.5
|
|||||
Other
Long-term Liabilities
|
476.5
|
459.9
|
|||||
Long-term
Obligations (Note 9)
|
2,182.4
|
2,180.7
|
|||||
Shareholders’
Equity:
|
|||||||
Preferred stock, $100 par value, 50,000 shares authorized; none
issued
|
|||||||
Common stock, $1 par value, 1,200,000,000 shares authorized; 429,563,224
and 424,240,292 shares issued
|
429.6
|
424.2
|
|||||
Capital
in excess of par value
|
11,928.9
|
11,810.4
|
|||||
Retained
earnings
|
1,912.3
|
1,773.4
|
|||||
Treasury
stock at cost, 7,633,117 and 7,635,184 shares
|
(253.7
|
)
|
(246.4
|
)
|
|||
Accumulated
other comprehensive items (Note 6)
|
215.6
|
150.2
|
|||||
14,232.7
|
13,911.8
|
||||||
$
|
21,171.9
|
$
|
21,262.2
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions except per share amounts)
|
2007
|
2006
|
|||||
Revenues
|
$
|
2,338.2
|
$
|
684.3
|
|||
Costs
and Operating Expenses:
|
|||||||
Cost
of revenues
|
1,458.3
|
371.7
|
|||||
Selling,
general and administrative expenses
|
620.3
|
202.5
|
|||||
Research
and development expenses
|
59.8
|
38.7
|
|||||
Restructuring
and other costs, net (Note 11)
|
7.4
|
3.6
|
|||||
2,145.8
|
616.5
|
||||||
Operating
Income
|
192.4
|
67.8
|
|||||
Other
Expense, Net (Note 4)
|
(26.7
|
)
|
(3.7
|
)
|
|||
Income
from Continuing Operations Before Provision for Income Taxes
|
165.7
|
64.1
|
|||||
Provision
for Income Taxes
|
(26.9
|
)
|
(20.5
|
)
|
|||
Income
from Continuing Operations
|
138.8
|
43.6
|
|||||
Income from Discontinued Operations (net of income tax provision
of $0.1
in 2007; Note 14)
|
0.1
|
—
|
|||||
Gain on Disposal of Discontinued Operations (net of income tax provision
of $1.9 in 2006; Note 14)
|
—
|
3.3
|
|||||
Net
Income
|
$
|
138.9
|
$
|
46.9
|
|||
Earnings
per Share from Continuing Operations (Note 5):
|
|||||||
Basic
|
$
|
.33
|
$
|
.27
|
|||
Diluted
|
$
|
.31
|
$
|
.26
|
|||
Earnings
per Share (Note 5):
|
|||||||
Basic
|
$
|
.33
|
$
|
.29
|
|||
Diluted
|
$
|
.31
|
$
|
.28
|
|||
Weighted
Average Shares (Note 5):
|
|||||||
Basic
|
420.1
|
163.0
|
|||||
Diluted
|
441.1
|
167.0
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Operating
Activities:
|
|||||||
Net
income
|
$
|
138.9
|
$
|
46.9
|
|||
Income
from discontinued operations
|
(0.1
|
)
|
—
|
||||
Gain
on disposal of discontinued operations
|
—
|
(3.3
|
)
|
||||
Income
from continuing operations
|
138.8
|
43.6
|
|||||
Adjustments to reconcile income from continuing operations to net
cash
provided by operating activities:
|
|||||||
Depreciation
and amortization
|
185.3
|
37.4
|
|||||
Change
in deferred income taxes
|
3.6
|
2.8
|
|||||
Noncash
equity compensation
|
13.8
|
6.1
|
|||||
Noncash charges for sale of inventories revalued at the date of
acquisition
|
36.2
|
—
|
|||||
Other
noncash expenses, net
|
10.6
|
(0.2
|
)
|
||||
Changes
in current accounts, excluding the effects of acquisitions and
dispositions:
|
|||||||
Accounts
receivable
|
(42.2
|
)
|
27.6
|
||||
Inventories
|
(46.7
|
)
|
(25.0
|
)
|
|||
Other
current assets
|
(36.5
|
)
|
(12.3
|
)
|
|||
Accounts
payable
|
42.9
|
1.5
|
|||||
Other
current liabilities
|
(87.3
|
)
|
(53.4
|
)
|
|||
Net
cash provided by continuing operations
|
218.5
|
28.1
|
|||||
Net
cash provided by discontinued operations
|
0.1
|
3.8
|
|||||
Net
cash provided by operating activities
|
218.6
|
31.9
|
|||||
Investing
Activities:
|
|||||||
Acquisitions,
net of cash acquired
|
(34.0
|
)
|
—
|
||||
Refund
of acquisition purchase price
|
4.6
|
—
|
|||||
Proceeds
from sale of available-for-sale investments
|
1.7
|
36.3
|
|||||
Purchases
of available-for-sale investments
|
(1.7
|
)
|
(35.0
|
)
|
|||
Purchases
of property, plant and equipment
|
(40.5
|
)
|
(13.3
|
)
|
|||
Proceeds
from sale of property, plant and equipment
|
1.3
|
0.3
|
|||||
Proceeds
from sale of product lines
|
—
|
8.9
|
|||||
Collection
of notes receivable
|
48.2
|
2.8
|
|||||
Increase
in other assets
|
(8.7
|
)
|
(1.1
|
)
|
|||
Other
|
—
|
0.2
|
|||||
Net
cash used in continuing operations
|
(29.1
|
)
|
(0.9
|
)
|
|||
Net
cash provided by discontinued operations
|
—
|
5.3
|
|||||
Net
cash (used in) provided by investing activities
|
$
|
(29.1
|
)
|
$
|
4.4
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Financing
Activities:
|
|||||||
Decrease
in short-term notes payable
|
$
|
(309.3
|
)
|
$
|
(41.3
|
)
|
|
Net
proceeds from issuance of company common stock
|
113.0
|
16.5
|
|||||
Tax
benefits from exercised stock options
|
9.8
|
4.3
|
|||||
Redemption
and repayment of long-term obligations
|
(7.6
|
)
|
—
|
||||
Net
cash used in financing activities
|
(194.1
|
)
|
(20.5
|
)
|
|||
Exchange
Rate Effect on Cash of Continuing Operations
|
8.1
|
0.7
|
|||||
Increase
in Cash and Cash Equivalents
|
3.5
|
16.5
|
|||||
Cash
and Cash Equivalents at Beginning of Period
|
667.4
|
214.3
|
|||||
Cash
and Cash Equivalents at End of Period
|
$
|
670.9
|
$
|
230.8
|
|||
Supplemental
Cash Flow Information:
|
|||||||
Fair
value of assets of acquired businesses
|
$
|
38.1
|
$
|
—
|
|||
Cash
paid for acquired businesses
|
(29.4
|
)
|
—
|
||||
Liabilities
assumed of acquired businesses
|
$
|
8.7
|
$
|
—
|
|||
Conversion
of subordinated convertible debentures
|
$
|
0.4
|
$
|
—
|
|||
Issuance
of restricted stock
|
$
|
12.8
|
$
|
0.9
|
1.
|
General
|
2.
|
Acquisitions
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Spectronex/Flux
|
Other
|
Total
|
|||||||
Purchase
Price:
|
||||||||||
Cash
paid (a)
|
$
|
25.8
|
$
|
5.4
|
$
|
31.2
|
||||
Cash
acquired
|
(1.8
|
)
|
—
|
(1.8
|
)
|
|||||
$
|
24.0
|
$
|
5.4
|
$
|
29.4
|
|||||
Allocation:
|
||||||||||
Current
assets
|
$
|
8.1
|
$
|
1.7
|
$
|
9.8
|
||||
Property,
plant and equipment
|
0.4
|
—
|
0.4
|
|||||||
Acquired
intangible assets
|
14.8
|
2.4
|
17.2
|
|||||||
Goodwill
|
9.1
|
1.6
|
10.7
|
|||||||
Liabilities
assumed
|
(8.4
|
)
|
(0.3
|
)
|
(8.7
|
)
|
||||
$
|
24.0
|
$
|
5.4
|
$
|
29.4
|
(a)
|
Includes
transaction costs.
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Spectronex/Flux
|
Other
|
Total
|
|||||||
Customer
Relationships
|
$
|
12.9
|
$
|
1.5
|
$
|
14.4
|
||||
Product
Technology
|
1.5
|
0.9
|
2.4
|
|||||||
Tradenames
|
0.4
|
—
|
0.4
|
|||||||
$
|
14.8
|
$
|
2.4
|
$
|
17.2
|
(In
millions)
|
Fisher
|
Cohesive
|
|||||
Fair
Value of Common Stock Issued to Fisher Shareholders
|
$
|
9,777.8
|
$
|
—
|
|||
Fair Value of Fisher Stock Options and Warrants Converted into Options
in
Company Common
Stock
|
502.3
|
—
|
|||||
Debt
Assumed
|
2,284.7
|
—
|
|||||
Cash
Paid Including Transaction Costs
|
38.5
|
71.3
|
|||||
Cash
Acquired
|
(392.0
|
)
|
(0.3
|
)
|
|||
$
|
12,211.3
|
$
|
71.0
|
||||
Allocation:
|
|||||||
Current
assets
|
$
|
1,919.3
|
$
|
5.7
|
|||
Property,
plant and equipment
|
953.2
|
1.0
|
|||||
Acquired
intangible assets
|
7,082.0
|
36.2
|
|||||
Goodwill
|
6,512.3
|
33.4
|
|||||
Other
assets
|
312.8
|
—
|
|||||
Liabilities
assumed
|
(4,021.5
|
)
|
(5.3
|
)
|
|||
Fair
value of convertible debt allocable to equity
|
(546.8
|
)
|
—
|
||||
$
|
12,211.3
|
$
|
71.0
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Fisher
|
Cohesive
|
|||||
Indefinite
Lives:
|
|||||||
Trademarks
|
$
|
1,326.9
|
$
|
—
|
|||
Definite
Lives:
|
|||||||
Customer
relationships
|
4,275.3
|
18.4
|
|||||
Product
technology
|
844.8
|
14.4
|
|||||
Tradenames
|
635.0
|
3.4
|
|||||
$
|
7,082.0
|
$
|
36.2
|
Three
Months Ended
|
||||
(In
millions except per share amounts)
|
April
1, 2006 (a)
|
|||
Revenues
|
$
|
2,096.4
|
||
Net
Income
|
$
|
(6.3
|
)
|
|
Earnings
per Share from Continuing Operations:
|
||||
Basic
|
$
|
(.02
|
)
|
|
Diluted
|
$
|
(.02
|
)
|
|
Earnings
Per Share:
|
||||
Basic
|
$
|
(.02
|
)
|
|
Diluted
|
$
|
(.02
|
)
|
(a)
|
Includes
$97 million pre-tax charge to cost of revenues for the sale of Fisher
inventories revalued at the date of merger, $15 million pre-tax charge
for
Fisher’s in-process research and development and $37 million pre-tax
charge for accelerated vesting of equity-based awards resulting from
the
change in control occurring at the date of the Fisher
merger.
|
2.
|
Acquisitions
(continued)
|
(In
millions)
|
Severance
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
Balance
at December 31, 2006
|
$
|
26.0
|
$
|
3.1
|
$
|
1.3
|
$
|
30.4
|
|||||
Reserves
established
|
3.2
|
3.6
|
1.3
|
8.1
|
|||||||||
Payments
|
(3.2
|
)
|
(0.1
|
)
|
(0.2
|
)
|
(3.5
|
)
|
|||||
Currency
translation
|
0.1
|
—
|
—
|
0.1
|
|||||||||
Balance
at March 31, 2007
|
$
|
26.1
|
$
|
6.6
|
$
|
2.4
|
$
|
35.1
|
(In
millions)
|
Severance
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
Balance
at December 31, 2006
|
$
|
2.2
|
$
|
2.7
|
$
|
0.1
|
$
|
5.0
|
|||||
Payments
|
(1.3
|
)
|
—
|
—
|
(1.3
|
)
|
|||||||
Balance
at March 31, 2007
|
$
|
0.9
|
$
|
2.7
|
$
|
0.1
|
$
|
3.7
|
3.
|
Business
Segment Information
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Revenues:
|
|||||||
Analytical
Technologies
|
$
|
1,006.2
|
$
|
504.6
|
|||
Laboratory
Products and Services
|
1,416.5
|
179.7
|
|||||
Eliminations
|
(84.5
|
)
|
—
|
||||
Consolidated
revenues
|
$
|
2,338.2
|
$
|
684.3
|
|||
Operating
Income:
|
|||||||
Analytical
Technologies (a)
|
$
|
189.8
|
$
|
71.5
|
|||
Laboratory
Products and Services (a)
|
185.7
|
25.5
|
|||||
Subtotal
reportable segments (a)
|
375.5
|
97.0
|
|||||
Cost
of revenues charges
|
(36.4
|
)
|
—
|
||||
Restructuring
and other costs, net
|
(7.4
|
)
|
(3.6
|
)
|
|||
Amortization
of acquisition-related intangible assets
|
(139.3
|
)
|
(25.6
|
)
|
|||
Consolidated
operating income
|
192.4
|
67.8
|
|||||
Other
expense, net (b)
|
(26.7
|
)
|
(3.7
|
)
|
|||
Income
from continuing operations before provision for income
taxes
|
$
|
165.7
|
$
|
64.1
|
|||
Equity-based
Compensation Expense:
|
|||||||
Analytical
Technologies
|
$
|
6.5
|
$
|
4.6
|
|||
Laboratory
Products and Services
|
7.3
|
1.5
|
|||||
Consolidated
equity-based compensation expense
|
$
|
13.8
|
$
|
6.1
|
|||
Amortization:
|
|||||||
Analytical
Technologies
|
$
|
52.6
|
$
|
6.5
|
|||
Laboratory
Products and Services
|
86.7
|
19.1
|
|||||
Consolidated
amortization
|
$
|
139.3
|
$
|
25.6
|
|||
Depreciation:
|
|||||||
Analytical
Technologies
|
$
|
20.4
|
$
|
7.2
|
|||
Laboratory
Products and Services
|
25.6
|
4.6
|
|||||
Consolidated
depreciation
|
$
|
46.0
|
$
|
11.8
|
(a)
|
Represents
operating income before certain charges to cost of revenues; restructuring
and other costs, net and amortization of acquisition-related
intangibles.
|
(b)
|
The
company does not allocate other income and expenses to its segments.
|
4.
|
Other
Income (Expense), Net
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Interest
Income
|
$
|
8.9
|
$
|
3.5
|
|||
Interest
Expense
|
(37.2
|
)
|
(7.7
|
)
|
|||
Other
Items, Net
|
1.6
|
0.5
|
|||||
$
|
(26.7
|
)
|
$
|
(3.7
|
)
|
5.
|
Earnings
per Share
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions except per share amounts)
|
2007
|
2006
|
|||||
Income
from Continuing Operations
|
$
|
138.8
|
$
|
43.6
|
|||
Income
from Discontinued Operations
|
0.1
|
—
|
|||||
Gain
on Disposal of Discontinued Operations
|
—
|
3.3
|
|||||
Net
Income for Basic Earnings per Share
|
138.9
|
46.9
|
|||||
Effect
of Convertible Debentures
|
—
|
0.4
|
|||||
Income Available to Common Shareholders, as Adjusted for Diluted
Earnings
per Share
|
$
|
138.9
|
$
|
47.3
|
|||
Basic
Weighted Average Shares
|
420.1
|
163.0
|
|||||
Effect
of:
|
|||||||
Convertible
debentures
|
11.7
|
1.9
|
|||||
Stock
options, restricted stock awards and warrants
|
9.3
|
2.1
|
|||||
Diluted
Weighted Average Shares
|
441.1
|
167.0
|
Basic
Earnings per Share:
|
|||||||
Continuing
operations
|
$
|
.33
|
$
|
.27
|
|||
Discontinued
operations
|
—
|
.02
|
|||||
$
|
.33
|
$
|
.29
|
||||
Diluted
Earnings per Share:
|
|||||||
Continuing
operations
|
$
|
.31
|
$
|
.26
|
|||
Discontinued
operations
|
—
|
.02
|
|||||
$
|
.31
|
$
|
.28
|
6.
|
Comprehensive
Income
|
7.
|
Equity-based
Compensation Expense
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Stock
Option Awards
|
$
|
9.3
|
$
|
5.4
|
|||
Restricted
Share/Unit Awards
|
4.5
|
0.7
|
|||||
Total
Equity-based Compensation Expense
|
$
|
13.8
|
$
|
6.1
|
Equity-based
compensation expense is included in the accompanying statement of
income
as follows:
|
Three
Months Ended
|
|||||||
|
March
31,
|
April
1,
|
|||||
(In
millions)
|
2007
|
2006
|
|||||
Cost
of Revenues
|
$
|
1.3
|
$
|
0.6
|
|||
Selling,
General and Administrative Expenses
|
12.0
|
5.2
|
|||||
Research
and Development Expenses
|
0.5
|
0.3
|
|||||
Total
Equity-based Compensation Expense
|
$
|
13.8
|
$
|
6.1
|
8.
|
Defined
Benefit Pension Plans
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Service
Cost
|
$
|
4.8
|
$
|
1.4
|
|||
Interest
Cost on Benefit Obligation
|
15.3
|
3.5
|
|||||
Expected
Return on Plan Assets
|
(16.1
|
)
|
(3.0
|
)
|
|||
Amortization
of Net Loss
|
1.2
|
0.9
|
|||||
Amortization
of Prior Service Costs
|
—
|
0.1
|
|||||
Net
Periodic Benefit Cost
|
$
|
5.2
|
$
|
2.9
|
Three
Months Ended
|
||||
(In
millions)
|
March
31, 2007
|
|||
Service
Cost
|
$
|
0.2
|
||
Interest
Cost on Benefit Obligation
|
0.4
|
|||
Net
Periodic Benefit Cost
|
$
|
0.6
|
9.
|
Swap
Arrangement
|
10.
|
Warranty
Obligations
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(In
millions)
|
2007
|
2006
|
|||||
Beginning
Balance
|
$
|
45.5
|
$
|
33.4
|
|||
Provision
charged to income
|
12.2
|
8.8
|
|||||
Usage
|
(7.9
|
)
|
(8.7
|
)
|
|||
Acquisitions
|
0.5
|
—
|
|||||
Adjustments
to previously provided warranties, net
|
0.5
|
(0.3
|
)
|
||||
Other,
net (a)
|
0.5
|
0.1
|
|||||
Ending
Balance
|
$
|
51.3
|
$
|
33.3
|
(a)
|
Primarily
represents the effects of currency
translation.
|
11.
|
Restructuring
and Other Costs, Net
|
(
(In millions)
|
Analytical
Technologies
|
Laboratory
Products
and
Services
|
Corporate
|
Total
|
|||||||||
Cost of Revenues
|
$
|
29.1
|
$
|
7.3
|
$
|
—
|
$
|
36.4
|
|||||
Restructuring
and Other Costs, Net
|
3.1
|
0.6
|
3.7
|
7.4
|
|||||||||
$
|
32.2
|
$
|
7.9
|
$
|
3.7
|
$
|
43.8
|
11.
|
Restructuring
and Other Costs, Net
(continued)
|
11.
|
Restructuring
and Other Costs, Net
(continued)
|
(In
millions)
|
Severance
|
Employee
Retention
(a)
|
Abandonment
of
Excess
Facilities
|
Other
|
Total
|
|||||||||||
Pre-2006
Restructuring Plans
|
||||||||||||||||
Balance
at December 31, 2006
|
$
|
1.8
|
$
|
0.3
|
$
|
9.4
|
$
|
0.6
|
$
|
12.1
|
||||||
Costs
incurred in 2007 (b)
|
0.5
|
—
|
0.2
|
0.1
|
0.8
|
|||||||||||
Reserves
reversed
|
(0.4
|
)
|
—
|
—
|
—
|
(0.4
|
)
|
|||||||||
Payments
|
(0.3
|
)
|
(0.3
|
)
|
(6.5
|
)
|
(0.1
|
)
|
(7.2
|
)
|
||||||
Balance
at March 31, 2007
|
$
|
1.6
|
$
|
—
|
$
|
3.1
|
$
|
0.6
|
$
|
5.3
|
||||||
2006
Restructuring Plans
|
||||||||||||||||
Balance
at December 31, 2006
|
$
|
4.0
|
$
|
0.8
|
$
|
2.7
|
$
|
—
|
$
|
7.5
|
||||||
Costs
incurred in 2007 (b)
|
0.1
|
1.4
|
0.2
|
1.0
|
2.7
|
|||||||||||
Payments
|
(1.1
|
)
|
(0.4
|
)
|
(1.1
|
)
|
(1.0
|
)
|
(3.6
|
)
|
||||||
Balance
at March 31, 2007
|
$
|
3.0
|
$
|
1.8
|
$
|
1.8
|
$
|
—
|
$
|
6.6
|
||||||
2007
Restructuring Plans
|
||||||||||||||||
Costs
incurred in 2007 (b)
|
$
|
2.1
|
$
|
0.2
|
$
|
0.2
|
$
|
1.7
|
$
|
4.2
|
||||||
Payments
|
(0.4
|
)
|
—
|
—
|
(1.5
|
)
|
(1.9
|
)
|
||||||||
Balance
at March 31, 2007
|
$
|
1.7
|
$
|
0.2
|
$
|
0.2
|
$
|
0.2
|
$
|
2.3
|
(a)
|
Employee-retention
costs are accrued ratably over the period through which employees
must
work to qualify for a payment.
|
(b)
|
Excludes
non-cash items including $0.1 million asset write down in the Analytical
Technologies segment.
|
12.
|
Litigation
and Related Contingencies
|
13.
|
Adoption
of FASB Interpretation No. 48
|
13.
|
Adoption
of FASB Interpretation No. 48
(continued)
|
14.
|
Discontinued
Operations
|
15.
|
Recent
Accounting Pronouncements
|
Three Months Ended | |||||||||||||
(Dollars
in millions)
|
March
31, 2007
|
April
1, 2006
|
|||||||||||
Analytical
Technologies
|
$
|
1,006.2
|
43.0%
|
|
$
|
504.6
|
73.7%
|
|
|||||
Laboratory
Products and Services
|
1,416.5
|
60.6%
|
|
179.7
|
26.3%
|
|
|||||||
Eliminations
|
(84.5
|
)
|
(3.6)%
|
|
—
|
0.0%
|
|
||||||
$
|
2,338.2
|
100%
|
|
$
|
684.3
|
100%
|
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
2007
|
2006
|
||||||
Operating Income Margin
|
|||||||
Consolidated
|
8.2%
|
|
9.9%
|
|
Three
Months Ended
|
|||||||
March
31,
|
April
1,
|
||||||
(Dollars
in millions)
|
2007
|
2006
|
|||||
Revenues:
|
|||||||
Analytical
Technologies
|
$
|
1,006.2
|
$
|
504.6
|
|||
Laboratory
Products and Services
|
1,416.5
|
179.7
|
|||||
Eliminations
|
(84.5
|
)
|
—
|
||||
Consolidated
Revenues
|
$
|
2,338.2
|
$
|
684.3
|
|||
Operating
Income:
|
|||||||
Analytical
Technologies
|
$
|
189.8
|
$
|
71.5
|
|||
Laboratory
Products and Services
|
185.7
|
25.5
|
|||||
Subtotal
Reportable Segments
|
375.5
|
97.0
|
|||||
Cost
of Revenues Charges
|
(36.4
|
)
|
—
|
||||
Restructuring
and Other Costs, Net
|
(7.4
|
)
|
(3.6
|
)
|
|||
Amortization
of Acquisition-related Intangible Assets
|
(139.3
|
)
|
(25.6
|
)
|
|||
Consolidated
Operating Income
|
$
|
192.4
|
$
|
67.8
|
Three
Months Ended
|
||||||||||
March
31,
|
April
1,
|
|||||||||
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||||||
Revenues
|
$
|
1,006.2
|
$
|
504.6
|
99%
|
|
||||
Operating
Income Margin
|
18.9%
|
|
14.2%
|
|
4.7
pts.
|
Three
Months Ended
|
||||||||||
March
31,
|
April
1,
|
|||||||||
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||||||
Revenues
|
$
|
1,416.5
|
$
|
179.7
|
688%
|
|
||||
Operating
Income Margin
|
13.1%
|
|
14.2%
|
|
(1.1)
pts.
|